Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS228 in subacute spinal cord injury
NCT06974968Phase 2Not yet recruiting
- Start
- May 2028
- Primary completion
- May 2031
- Modality
- Neural Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal cord injury (SCI) comparing XS228 Interventional Group with Placebo Control Group (2 arms). Primary endpoint: Improvement in ASIA Impairment Scale (AIS) grade at Day 360. Planned start May 2028; status: not yet recruiting.
02
Drugs
XS228
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06974968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974968.